LH Quote, Financials, Valuation and Earnings

Quest Diagnostics, Inc. has a net margin of 7.34% compared to Labcorp Holdings, Inc.'s net margin of 9.13%. Labcorp Holdings, Inc.'s return on equity of 10.25% beat Quest Diagnostics, Inc.'s return on equity of 14.33%.

Labcorp Holdings, Inc. has a consensus price target of $299.71, signalling upside risk potential of 18.05%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $198.06 which suggests that it could grow by 12.57%. Given that Labcorp Holdings, Inc. has higher upside potential than Quest Diagnostics, Inc., analysts believe Labcorp Holdings, Inc. is more attractive than Quest Diagnostics, Inc..

Labcorp Holdings, Inc. has a beta of 0.989, which suggesting that the stock is 1.121% less volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.618, suggesting its less volatile than the S&P 500 by 38.214%.

Labcorp Holdings, Inc. has a quarterly dividend of $0.72 per share corresponding to a yield of 1.13%. Quest Diagnostics, Inc. offers a yield of 1.79% to investors and pays a quarterly dividend of $0.80 per share. Labcorp Holdings, Inc. pays 32.58% of its earnings as a dividend. Quest Diagnostics, Inc. pays out 39.15% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings, Inc. quarterly revenues are $3.6B, which are larger than Quest Diagnostics, Inc. quarterly revenues of $2.8B. Labcorp Holdings, Inc.'s net income of $261.5M is higher than Quest Diagnostics, Inc.'s net income of $257M. Notably, Labcorp Holdings, Inc.'s price-to-earnings ratio is 24.93x while Quest Diagnostics, Inc.'s PE ratio is 20.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings, Inc. is 1.55x versus 1.83x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Danaher Corp. has a net margin of 7.34% compared to Labcorp Holdings, Inc.'s net margin of 15%. Labcorp Holdings, Inc.'s return on equity of 10.25% beat Danaher Corp.'s return on equity of 6.87%.

Labcorp Holdings, Inc. has a consensus price target of $299.71, signalling upside risk potential of 18.05%. On the other hand Danaher Corp. has an analysts' consensus of $258.09 which suggests that it could grow by 12.06%. Given that Labcorp Holdings, Inc. has higher upside potential than Danaher Corp., analysts believe Labcorp Holdings, Inc. is more attractive than Danaher Corp..

Labcorp Holdings, Inc. has a beta of 0.989, which suggesting that the stock is 1.121% less volatile than S&P 500. In comparison Danaher Corp. has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.801%.

Labcorp Holdings, Inc. has a quarterly dividend of $0.72 per share corresponding to a yield of 1.13%. Danaher Corp. offers a yield of 0.56% to investors and pays a quarterly dividend of $0.32 per share. Labcorp Holdings, Inc. pays 32.58% of its earnings as a dividend. Danaher Corp. pays out 20.42% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings, Inc. quarterly revenues are $3.6B, which are smaller than Danaher Corp. quarterly revenues of $6.1B. Labcorp Holdings, Inc.'s net income of $261.5M is lower than Danaher Corp.'s net income of $908M. Notably, Labcorp Holdings, Inc.'s price-to-earnings ratio is 24.93x while Danaher Corp.'s PE ratio is 47.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings, Inc. is 1.55x versus 6.84x for Danaher Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health, Inc. has a net margin of 7.34% compared to Labcorp Holdings, Inc.'s net margin of -34.97%. Labcorp Holdings, Inc.'s return on equity of 10.25% beat Guardant Health, Inc.'s return on equity of -8518.58%.

Labcorp Holdings, Inc. has a consensus price target of $299.71, signalling upside risk potential of 18.05%. On the other hand Guardant Health, Inc. has an analysts' consensus of $114.05 which suggests that it could grow by 10.75%. Given that Labcorp Holdings, Inc. has higher upside potential than Guardant Health, Inc., analysts believe Labcorp Holdings, Inc. is more attractive than Guardant Health, Inc..

Labcorp Holdings, Inc. has a beta of 0.989, which suggesting that the stock is 1.121% less volatile than S&P 500. In comparison Guardant Health, Inc. has a beta of 1.579, suggesting its more volatile than the S&P 500 by 57.876%.

Labcorp Holdings, Inc. has a quarterly dividend of $0.72 per share corresponding to a yield of 1.13%. Guardant Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Labcorp Holdings, Inc. pays 32.58% of its earnings as a dividend. Guardant Health, Inc. pays out -- of its earnings as a dividend. Labcorp Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings, Inc. quarterly revenues are $3.6B, which are larger than Guardant Health, Inc. quarterly revenues of $265.2M. Labcorp Holdings, Inc.'s net income of $261.5M is higher than Guardant Health, Inc.'s net income of -$92.7M. Notably, Labcorp Holdings, Inc.'s price-to-earnings ratio is 24.93x while Guardant Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings, Inc. is 1.55x versus 14.16x for Guardant Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GeneDx Holdings Corp. has a net margin of 7.34% compared to Labcorp Holdings, Inc.'s net margin of -6.54%. Labcorp Holdings, Inc.'s return on equity of 10.25% beat GeneDx Holdings Corp.'s return on equity of 0.82%.

Labcorp Holdings, Inc. has a consensus price target of $299.71, signalling upside risk potential of 18.05%. On the other hand GeneDx Holdings Corp. has an analysts' consensus of $170.89 which suggests that it could grow by 27.73%. Given that GeneDx Holdings Corp. has higher upside potential than Labcorp Holdings, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Labcorp Holdings, Inc..

Labcorp Holdings, Inc. has a beta of 0.989, which suggesting that the stock is 1.121% less volatile than S&P 500. In comparison GeneDx Holdings Corp. has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.538%.

Labcorp Holdings, Inc. has a quarterly dividend of $0.72 per share corresponding to a yield of 1.13%. GeneDx Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Labcorp Holdings, Inc. pays 32.58% of its earnings as a dividend. GeneDx Holdings Corp. pays out -- of its earnings as a dividend. Labcorp Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings, Inc. quarterly revenues are $3.6B, which are larger than GeneDx Holdings Corp. quarterly revenues of $116.7M. Labcorp Holdings, Inc.'s net income of $261.5M is higher than GeneDx Holdings Corp.'s net income of -$7.6M. Notably, Labcorp Holdings, Inc.'s price-to-earnings ratio is 24.93x while GeneDx Holdings Corp.'s PE ratio is 2,218.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings, Inc. is 1.55x versus 9.54x for GeneDx Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.